Ser525
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser525  -  RAP1GAP (human)

Site Information
AGQKtPDsGHVSQEP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450258

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
bone cancer ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 , 2 ) , HeLa (cervical) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
PLK1 (human) ( 1 )
Kinases, in vitro:
PLK1 (human) ( 1 )
Treatments:
colforsin ( 2 ) , TSH ( 2 )

Downstream Regulation
Effects of modification on RAP1GAP:
molecular association, regulation ( 1 ) , protein degradation ( 1 , 2 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
cell growth, induced ( 1 )
Induce interaction with:
BTRC (human) ( 1 )

References 

1

Wang D, et al. (2014) PLK1 and β-TrCP-Dependent Ubiquitination and Degradation of Rap1GAP Controls Cell Proliferation. PLoS One 9, e110296
25329897   Curated Info

2

Tsygankova OM, Feshchenko E, Klein PS, Meinkoth JL (2004) Thyroid-stimulating hormone/cAMP and glycogen synthase kinase 3beta elicit opposing effects on Rap1GAP stability. J Biol Chem 279, 5501-7
14660640   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.